Nextrials lauded for its work with industry standards organizations to advance integration of clinical trial data collection platforms with electronic health records.
Nextrials Nominated for the World Technology Awards
Nextrials lauded for its work with industry standards organizations to advance integration of clinical trial data collection platforms with electronic health records
San Ramon, CA – April 27, 2009 –
Nextrials, Inc. (www.nextrials.com <
http://www.nextrials.com
> ), a leader in clinical research software and services, today announced that it is a nominee in the World Technology Network’s 2009 World Technology Awards. Since 2000, this award has been presented annually to outstanding science and technology innovators producing work likely to have the greatest long-term significance. Nextrials was singled out for its recent progress toward integrating Prism®, its electronic data capture and clinical trial management platform, with platforms used to manage electronic health records in the healthcare setting.
“On average, it costs over $1 billion to develop a new drug, and up to 12 years to complete the clinical trials process, obtain approvals and deliver the drug to market; as it stands, it is a virtually unsustainable system,” noted James Rogers, co-founder and CEO of Nextrials. “The biopharmaceutical industry has made great strides in eliminating manual, paper-based systems to help alleviate development costs by using electronic data capture and management platforms such as Prism. Now, by achieving the integration of these platforms with those used to maintain electronic patient records, we can revitalize the market through even more savings in labor, cost and time.”
Nextrials was nominated for its contribution to the industry, specifically through participation with industry organizations such as the Clinical Data Interchange Standards Consortium (CDISC) and Integrating the Healthcare Enterprise (IHE), in developing and implementing EDC and EHR integration standards.
“The World Technology Awards program is a very inspiring way to identify and honor the most innovative organizations in the technology world,” said James P. Clark, founder and Chairman of the World Technology Network. “Nextrials’ forward-thinking approach will undoubtedly hold long-term significance to both the pharmaceutical and healthcare industries.”
Nextrials’ award-winning Prism melds sophisticated clinical trial management functionality with electronic data capture in a single, integrated package. It is currently used worldwide by biopharmaceutical and medical device R&D teams developing novel treatments and therapeutics. Visitors to the 18th Annual Partnerships with CROs Conference, being held April 28-30 at the Rosen Shingle Creek Hotel in Orlando, FL, can view a demonstration of Prism in Nextrials’ booth #601.
About The World Technology Network
The World Technology Network is a New York-headquartered organization that was created to "encourage serendipity” - happy accidents - amongst those individuals and companies deemed by their peers to be the most innovative in the science and technology world. The WTN's areas of interest range from IT and communications to biotech, energy, materials, space, as well as related fields such as finance, marketing, policy, law, design, and ethics. For more information, visit
http://www.wtn.net/
.
About Nextrials
Founded by pharmaceutical researchers in 1999, Nextrials offers today’s most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism®, its award-winning Electronic Data Capture (EDC) solution, has been used at over 1,000 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com <
http://www.nextrials.com
> , follow us on Twitter @Nextrials, or call 925-355-3000.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.